Protagonist Therapeutics (PTGX) Tax Provisions (2018 - 2026)

Protagonist Therapeutics has reported Tax Provisions for 7 years, with the latest figure at -$1.5 million in Q1 2026.

• Quarterly Tax Provisions changed N/A year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$636000.0 (down 170.67% YoY) and the FY2025 annual result came in at $838000.0, down 80.14% from the prior year.
• Tax Provisions declined to -$1.5 million in Q1 2026 per PTGX's latest filing, from $666000.0 in the prior quarter.
• Over five years, Tax Provisions peaked at $3.3 million in Q1 2024 and troughed at -$16.6 million in Q4 2023.
• A 4-year average of -$1.6 million and a median of -$110000.0 in 2024 frame the typical range for Tax Provisions.
• The widest YoY moves for Tax Provisions: up 128.57% in 2025, down 67.03% in 2025.
• Over 4 years, Tax Provisions stood at -$16.6 million in 2023, then jumped by 112.18% to $2.0 million in 2024, then slumped by 67.03% to $666000.0 in 2025, then slumped by 325.53% to -$1.5 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered -$1.5 million, $666000.0, and $200000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.